{"nctId":"NCT01462929","briefTitle":"Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2011-11"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":414,"armGroups":[{"label":"Aclidinium bromide","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide"]},{"label":"Tiotropium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tiotropium"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium bromide","otherNames":[]},{"name":"Tiotropium","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male and female patients aged ≥40 with stable moderate to severe COPD (GOLD guidelines).\n* Post-salbutamol (FEV1) \\< 80% and ≥ 30% of predicted normal value and Post-salbutamol FEV1/FVC \\< 70%.\n* Current or ex-smokers of 10 ≥pack-years.\n\nExclusion Criteria:\n\n* Patients with no history or current diagnosis of asthma.\n* No evidence of an exacerbation within 6 weeks prior to the screening visit.\n* No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.\n* No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Normalised Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over the 24-h Period After 6 Weeks of Treatment","description":"Change from baseline in normalised FEV1 area under the curve over the 24-h period immediately after morning Investigational Medicinal Product administration (AUC0-24h ) after 6 weeks on treatment. The normalised AUC were calculated by means of a trapezoidal method, dividing by the corresponding time interval.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.065","spread":"0.017"},{"groupId":"OG001","value":"0.055","spread":"0.018"},{"groupId":"OG002","value":"-0.085","spread":"0.023"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Normalised FEV1 Area Under the Curve Over the 12-h Night-time Period After 6 Weeks of Treatment","description":"Change from baseline in normalised FEV1 area under the curve over the 12-h night-time period (AUC12-24) after 6 weeks of treatment. The normalised AUC were calculated by means of a trapezoidal method, dividing by the corresponding time interval.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.032","spread":"0.017"},{"groupId":"OG001","value":"-0.006","spread":"0.018"},{"groupId":"OG002","value":"-0.128","spread":"0.024"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":171},"commonTop":["Nasopharyngitis","Headache"]}}}